Hamlet BioPharma (HAMLET B) Stock Overview
Engages in the development of drugs for the treatment and prevention of cancer in Sweden. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
HAMLET B Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Hamlet BioPharma AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 4.07 |
| 52 Week High | SEK 5.00 |
| 52 Week Low | SEK 2.49 |
| Beta | 0.72 |
| 1 Month Change | -2.52% |
| 3 Month Change | -5.90% |
| 1 Year Change | -18.54% |
| 3 Year Change | -4.01% |
| 5 Year Change | -40.22% |
| Change since IPO | 74.21% |
Recent News & Updates
Recent updates
Is Hamlet BioPharma (NGM:HAMLET B) In A Good Position To Deliver On Growth Plans?
Feb 16
Is Hamlet Pharma (NGM:HAMLET B) In A Good Position To Invest In Growth?
Jul 04Here's Why We're Watching Hamlet Pharma's (NGM:HAMLET B) Cash Burn Situation
Mar 04We Think Hamlet Pharma (NGM:HAMLET B) Can Afford To Drive Business Growth
Nov 10We Think Hamlet Pharma (NGM:HAMLET B) Can Easily Afford To Drive Business Growth
Jun 17Companies Like Hamlet Pharma (NGM:HAMLET B) Are In A Position To Invest In Growth
Oct 12Will Hamlet Pharma (NGM:HAMLET B) Spend Its Cash Wisely?
Mar 17Shareholder Returns
| HAMLET B | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | -2.0% | 4.0% | 0.4% |
| 1Y | -18.5% | -6.3% | -4.0% |
Return vs Industry: HAMLET B underperformed the Swedish Biotechs industry which returned -6.7% over the past year.
Return vs Market: HAMLET B underperformed the Swedish Market which returned -4.3% over the past year.
Price Volatility
| HAMLET B volatility | |
|---|---|
| HAMLET B Average Weekly Movement | 7.1% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in SE Market | 13.4% |
| 10% least volatile stocks in SE Market | 4.2% |
Stable Share Price: HAMLET B has not had significant price volatility in the past 3 months compared to the Swedish market.
Volatility Over Time: HAMLET B's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 7 | Catharina Svanborg | www.hamletpharma.com |
Hamlet BioPharma AB (publ) engages in the development of drugs for the treatment and prevention of cancer in Sweden. It is developing HAMLET, a tumoricidal protein-lipid complex formed by two generally regarded as safe (GRAS) molecules found in human milk for various oncology markets, including colon, bladder, and cervix cancers, as well as primary or metastatic brain tumors. The company’s products under development include Alpha1H for the treatment of bladder cancer and brain tumors; and BAMLET for the treatment of colon and oral cancer.
Hamlet BioPharma AB (publ) Fundamentals Summary
| HAMLET B fundamental statistics | |
|---|---|
| Market cap | SEK 722.29m |
| Earnings (TTM) | -SEK 48.70m |
| Revenue (TTM) | SEK 178.07k |
Is HAMLET B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HAMLET B income statement (TTM) | |
|---|---|
| Revenue | SEK 178.07k |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 178.07k |
| Other Expenses | SEK 48.87m |
| Earnings | -SEK 48.70m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
Nov 14, 2025
| Earnings per share (EPS) | -0.27 |
| Gross Margin | 100.00% |
| Net Profit Margin | -27,346.83% |
| Debt/Equity Ratio | 0% |
How did HAMLET B perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/06/04 13:21 |
| End of Day Share Price | 2025/06/04 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Hamlet BioPharma AB (publ) is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.